Phase 1 Safety and Immunogenicity of DNA/NYVAC Prime Boost Vaccination With/Without Emtricitabine/Tenofovir
Protocol Title
A phase 1 clinical trial to evaluate the safety and immunogenicity of DNA/NYVAC prime boost vaccination with or without oral emtricitabine/tenofovir or vaginal tenofovir 1% gel in healthy, HIV-1–uninfected adult female participants
DAIDS Protocol ID
11852
Status
Withdrawn
Countries
South Africa
United States
Study Sites